Hot topics in the diagnosis and management of skin and soft-tissue infections

Esposito, Silvano; Bassetti, Matteo; Bonnet, É.; Bouza, Emilio; Chan, Mónica; Simone, Giuseppe De; Dryden, Matthew; Gould, Ian M.; Lye, David C.; Saeed, Kordo; Segreti, John; Ünal, Serhat; Yalcin, Ata Nevzat

doi:10.1016/j.ijantimicag.2016.04.011

Cited by 44 publications

(27 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, microbiological tests are not always needed to pose the clinical diagnosis of some less severe SSTIs or when the aetiology is supposed to be known. 21,22 Indeed, in 30.7% of the cases in this study, the patients did not undergo a microbiological test as it was considered unnecessary (most often for cellulitis, erysipelas and small subcutaneous abscess) and antimicrobial treatment was started without a microbial diagnosis. This applies to a new clinical entity, recently defined by the US Food and Drug Administration (FDA): acute bacterial skin and skin-structure infection (ABSSSI).…”

Section: Discussionmentioning

confidence: 95%

Epidemiology and Microbiology of Skin and Soft Tissue Infections: Preliminary Results of a National Registry

Esposito

Simone

Pan

et al. 2018

Journal of Chemotherapy

Self Cite

View full text Add to dashboard Cite

Skin and soft tissue infections (SSTIs) represent a wide range of clinical conditions characterized by a considerable variety of clinical presentations and severity. Their aetiology can also vary, with numerous possible causative pathogens. While other authors previously published analyses on several types of SSTI and on restricted types of patients, we conducted a large nationwide surveillance programme on behalf of the Italian Society of Infectious and Tropical Diseases to assess the clinical and microbiological characteristics of the

show abstract

Section: Discussionmentioning

confidence: 95%

Epidemiology and Microbiology of Skin and Soft Tissue Infections: Preliminary Results of a National Registry

Esposito

Simone

Pan

et al. 2018

Journal of Chemotherapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…1 Superficial incisional (involving only skin or subcutaneous tissue of the incision) SSIs are considered, together with cellulitis and major cutaneous abscesses, a subgroup ABSSSIs (Acute Bacterial Skin and Skin Structure Infections) 2 and belong to the broader chapter of Skin and Soft Tissue Infections. 3,4 U.S. CDC estimates that patients with SSIs are at 2-11 times higher risk of death and 75% of deaths among these patients are directly attributable to SSI. In addition to the negative impact on patient outcomes, SSIs are associated with substantial economic costs.…”

Section: Surgical Site Infections (Ssis) Overviewmentioning

confidence: 99%

The role of dalbavancin in the multi-disciplinary management of wound infections in orthopaedic surgery

Arena

Romanini

Rosi

et al. 2017

Journal of Chemotherapy

View full text Add to dashboard Cite

Antimicrobial resistance is continuously increasing among bacterial clinical isolates (especially methicillin resistance in Staphylococcus aureus, MRSA), negatively impacting on outcomes of patients with Surgical Site Infections (SSIs). A multi-disciplinary team work is essential for SSIs prevention and for the choice of antibiotic therapy of orthopaedic SSIs. In particular, an Antibiotic Stewardship (AS) approach is recommended for preserving the activity of old and new antimicrobials. Dalbavancin is a novel antimicrobial agent, belonging to the lipoglycopeptides family, recently approved by FDA for the treatment of ABSSSIs (Acute Bacterial Skin and Skin Structure Infections) and can be considered as a candidate for the treatment of orthopaedic superficial SSIs. An antimicrobial activity directed against MRSA and other multi-resistant Gram-positive pathogens, a bactericidal effect and an extremely extended half-life are among key features of this drug. Dalbavancin gives to clinicians the option to provide an intravenous antimicrobial agent shown to be as effective as conventional therapies, without requiring prolonged admission into the hospital, drastically reducing the length of hospital stay (without reducing the treatment compliance) and total cost per patient. In this paper, we analyze general, microbiological and pharmacological features of dalbavancin, aiming at supporting clinicians while positioning this drug in the context of orthopaedic SSIs.

show abstract

“…Ortalama tedavi süresi beş gündür ancak klinik düzelme olmadığı durumlarda tedavi süresi iki haftaya kadar uzatılabilir. Antibiyotik tedavisine ek olarak selülit gelişen ekstremitenin elevasyonu sağlanmalı, predispozan faktörler tespit edilmeli ve ortadan kaldırılmalıdır [15,16].…”

Section: Introductionunclassified

Assessment of the risk factors of recurrent lower extremity cellulits and the effect of clinical and laboratory findings on treatment response

2019

View full text Add to dashboard Cite

Hot topics in the diagnosis and management of skin and soft-tissue infections

Cited by 44 publications

References 74 publications

Epidemiology and Microbiology of Skin and Soft Tissue Infections: Preliminary Results of a National Registry

Epidemiology and Microbiology of Skin and Soft Tissue Infections: Preliminary Results of a National Registry

The role of dalbavancin in the multi-disciplinary management of wound infections in orthopaedic surgery

Assessment of the risk factors of recurrent lower extremity cellulits and the effect of clinical and laboratory findings on treatment response

Contact Info

Product

Resources

About